Our Ambition Is To Change Attitudes And Make Uninhibited Living A Habit.
Express Pharma|March 01-15, 2019

Nikhil Chopra, India Business Head, Cipla speaks on busting myths on asthma and Ciplas' #BerokZindagi initiative to lead a better life in a conversation with Prabhat Prakash

Our Ambition Is To Change Attitudes And Make Uninhibited Living A Habit.

What is the incidence rate of asthma in India? How huge is the disease burden?

In India, 93 million people suffer from chronic respiratory diseases, of which 38 million people are diagnosed as asthmatics. One must note that these chronic respiratory diseases cause the second largest mortality after cardiovascular diseases. (Source: https:// www.thelancet.com/journals/lan glo/article/PIIS2214109X(18)30409-1/fulltext) Doctors across the nation see an average of around 30-40 patients suffering from respiratory diseases like asthma on a daily basis, and there is absolutely no sign of reduction of the disease burden. In fact, last year saw a whopping 25 per cent increase in the number of people suffering from respiratory symptoms compared to the previous year. It is estimated that one-third of the population will develop asthma at some point, and mostly before the age of 20. Factors such as the rise of particulate matter in the air, pollen, smoking, food habits, nutritional deficiency, hereditary predisposition and largely ignorance amongst parents only increase the prevalence of the disease.

As asthma is a chronic disease it poses a lot of economic burden on the patient. Is cost a deterrent?

Higher initial costs tend to hinder the adoption of consistent therapy for asthma in the lower socio-economic groups. However, if one considers the price bracket of inhalers which is the mainstay for treatment, a patient needs to shell out a daily cost of less than ̀ 10. Also, the range of solutions that we offer for asthma in India is not available anywhere else at such accessible prices. Hence, we can say that in terms of reasons for not adopting inhalation therapy for asthma, the lack of awareness and prevailing misconceptions about it far surpass the factor of cost burden for non-adoption.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM EXPRESS PHARMAView all
MAKING SUSTAINABILITY SUSTAINABLE
Express Pharma

MAKING SUSTAINABILITY SUSTAINABLE

Driven by stringent regulations, rising investor expectations, consumer demand, and operational considerations, MSME pharma companies need to carefully balance their sustainability goals with financial viability

time-read
10+ mins  |
September 2024
New energy recovery system for tablet coaters
Express Pharma

New energy recovery system for tablet coaters

Upto 50 per cent less steam energy consumption

time-read
5 mins  |
September 2024
The future of pharma logistics: Trends, challenges, and opportunities
Express Pharma

The future of pharma logistics: Trends, challenges, and opportunities

Nikhil Agarwal, President, CJ Darcl Logistics explains that the future of pharma logistics is a thrilling frontier shaped by technological advancements, regulatory challenges, and the imperative of sustainability. As the industry transforms, logistics providers must embrace innovative solutions and adapt to shifting demands

time-read
3 mins  |
September 2024
Achieving Aatmanirbharta In APIs Are We On The Right Track?
Express Pharma

Achieving Aatmanirbharta In APIs Are We On The Right Track?

As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a key goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats

time-read
9 mins  |
August 2021
Yokogawa launches OpreX Data Model Broker
Express Pharma

Yokogawa launches OpreX Data Model Broker

A plant data transformation platform, OpreX automatically verifies discrepancies and inconsistencies in data to improve efficiency in plant construction and operation

time-read
2 mins  |
August 2021
Understanding the nuances of generics injectables
Express Pharma

Understanding the nuances of generics injectables

At a webinar, explaining the West Pharma's AccelTRA Components Program, industry experts explained why the use of glass vials and stoppers as primary container closure systems (CCS) has become crucial

time-read
6 mins  |
August 2021
Trending in nutraceuticals: Science meets sustainability
Express Pharma

Trending in nutraceuticals: Science meets sustainability

Zeljko Pockaj, Vice President, Global Pharmaceutical Industry, mentions the key trends that are believed to drive innovations and formulations for nutraceuticals’ development around the globe

time-read
3 mins  |
August 2021
The growth of e-pharmacies in India
Express Pharma

The growth of e-pharmacies in India

Rahul Nath Choudhury, Research fellow, ICWA, explains what motivates people in the pharma industry to invest into e-pharmacies, along with various other growth factors associated with these

time-read
4 mins  |
August 2021
Xylitol and Maltitol: Low-calorie sugar alternatives
Express Pharma

Xylitol and Maltitol: Low-calorie sugar alternatives

Polyols like Xylitol and Maltitol offer important health benefits. Unlike general sugar-free sweeteners, these do not have any bitter-after taste

time-read
4 mins  |
August 2021
Single-use TC gaskets and their importance
Express Pharma

Single-use TC gaskets and their importance

Depending on the application, gaskets are manufactured by different types of Material of Construction (MOC) such as Silicone, EPDM, Viton (FKM), Nitrile, Neoprene, PTFE, etc.

time-read
2 mins  |
August 2021